AZN241018C82500
- 0.02
- 0.000.00%
AstraZeneca Newsroom
Unusual Options Activity: ACI, TAL and Others Attract Market Bets, ACI V/OI Ratio Reaches 625.0
EST Oct 18th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
HK stock unusual movement | cspc pharma (01093) is currently up more than 7%, cspc innovation pharmaceutical plans to acquire cspc pharma bak, cspc pharma reaches cooperation with astrazeneca.
CSPC Pharma (01093) is now up over 7%, as of the time of writing, up 6.91%, trading at 6.5 Hong Kong dollars, with a turnover of 0.818 billion Hong Kong dollars.
Astrazeneca (AZN.US) new drug tremelimumab combined with durvalumab therapy applied for marketing approval in China.
The latest announcement on the official website of the China National Pharmaceutical Regulatory Agency's Drug Evaluation Center (CDE) shows that applications for the market approval of two new pharmaceuticals from astrazeneca (AZN.US) have been accepted. The specific indications have not been disclosed yet.
Unusual Options Activity: AZN, GRMN and Others Attract Market Bets, AZN V/OI Ratio Reaches 166.7
EST Oct 17th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
AstraZeneca (AZN): High-Growth UK Stock With Strong Pipeline
DIA's Canada Annual Meeting to Address Precision Regulation Initiatives and Advancements in Clinical Trials
The Zacks Analyst Blog Highlights AstraZeneca, Accenture, AT&T and National Presto Industries
AstraZeneca (AZN) Receives a Hold From Jefferies
Hong Kong stock unusual movement | hutchmed (china) (00013) rose nearly 6%, the combination therapy of Tauri and Vori shows a clinically significant response rate.
hutchmed (china) (00013) rose nearly 6%, as of the time of publication, up 5.92%, at 32.2 Hong Kong dollars, with a turnover of 54.3401 million Hong Kong dollars.
Top Research Reports for AstraZeneca, Accenture & AT&T
Hutchmed, AstraZeneca's Lung Cancer Combo Shrinks Tumors in Mid-stage Study
AstraZeneca Hits 4-week High
AstraZeneca Advances Science of Infectious Disease Protection at IDWeek 2024
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China
Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.
On October 14, the official website of the China National Medical Products Administration (NMPA) reported that the new indication for lung cancer of the injection monoclonal antibody trastuzumab deruxtecan (Enhertu) applied by Daiichi Sankyo has been approved for marketing. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate developed jointly by Astrazeneca (AZN.US) and Daiichi Sankyo.
AstraZeneca Expanding R&D Pipeline in China
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing